{"preliminary_commentary":{"by_channel":{"youtube":7,"x_thread":5,"podcast":3,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06769126\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"S2409","nct_id":"NCT06769126","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=s2409-nct06769126. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 positive or patients with subtype P ES-SCLC.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort A, Arm 1 (durvalumab)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 positive or patients with subtype P ES-SCLC.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle and saruparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort A, Arm 2 (durvalumab, saruparib)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 negative.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort B, Arm 1 (durvalumab)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 negative.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 8 and ceralasertib PO BID on days 1-7 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort B, Arm 2 (durvalumab, ceralasertib)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype I.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort C, Arm 1 (durvalumab)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype I.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 and monalizumab IV over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort C, Arm 2 (durvalumab, monalizumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"conditions":["Extensive Stage Lung Small Cell Carcinoma","Lung Small Cell Carcinoma, A Subtype","Lung Small Cell Carcinoma, I Subtype","Lung Small Cell Carcinoma, N Subtype","Lung Small Cell Carcinoma, P Subtype"],"enrollment":{"count":900,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Ceralasertib","otherNames":["AZD6738"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Durvalumab","otherNames":["Imfinzi","Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","MEDI 4736","MEDI-4736","MEDI4736"],"type":"BIOLOGICAL"},{"name":"Etoposide","otherNames":["Demethyl Epipodophyllotoxin Ethylidine Glucoside","EPEG","Lastet","Toposar","Vepesid","VP 16","VP 16-213","VP 16213","VP-16","VP-16-213","VP-16213","VP16","VP16213"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Monalizumab","otherNames":["Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody","IPH-2201","IPH2201","NN-8765","NN8765","NN8765-3658"],"type":"BIOLOGICAL"},{"name":"Platinum Compound","otherNames":["Platinum Agents","Platinum-Based Chemotherapeutic Agent"],"type":"DRUG"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging","PT"],"type":"PROCEDURE"},{"name":"Saruparib","otherNames":["AZD 5305","AZD-5305","AZD5305","PARP Inhibitor AZD5305"],"type":"DRUG"},{"name":"Thoracic Radiation Therapy","otherNames":["Thoracic Radiotherapy"],"type":"RADIATION"}],"last_update":"2026-03-30","lead_sponsor":"SWOG Cancer Research Network","official_title":"PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Screen success rate (Screening)","timeFrame":"Up to 3 years"},{"measure":"Progression-free survival (PFS) (Cohort A)","timeFrame":"From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years"},{"measure":"PFS (Cohort B)","timeFrame":"From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years"},{"measure":"PFS (Cohort C)","timeFrame":"From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years"}],"references":[],"start_date":{"date":"2025-11-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study","url":"https://clinicaltrials.gov/study/NCT06769126"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/s2409-nct06769126"}